Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 68 CLL: FC versus FC + low-dose alemtuzumab in previously untreated high-risk CLL
2005-000309-75Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- Jul 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of alemtuzumab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Progression-free survival. Started Jul 2005; status: completed.
02
Drugs
alemtuzumabfludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2005-000309-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000309-75.